chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Fatigue; Fever; Mild joint achiness; Neck muscles sore; Pressure in head; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the arm left on 24Mar2021 at 16:15 (at the age of 68-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had food, grass and sesame seeds allergy. Concomitant medications included hydrochlorothiazide, valsartan (VALSARTAN HCTZ), amlodipine (MANUFACTURER UNKNOWN), rosuvastatin (MANUFACTURER UNKNOWN) and levothyroxine (MANUFACTURER UNKNOWN) received within 2 weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the arm left on 03Mar2021 at 16:45 (at the age of 68-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25Mar2021 at 08:00 the patient experienced fatigue, fever, mild joint achiness, neck muscles sore and pressure in head. No therapeutic measures were taken as a result of the events. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the event fatigue, fever, mild joint achiness, neck muscles sore and pressure in head was recovered on an unspecified date.    No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache
Clinical narrative: Chills; headache; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 31Mar2021 at 14:45(at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included migraine, genetic asymptomatic carrier for familial mediterranean fever and iodine allergy. In the year 2019 the patient received yellow fever vaccine, measles, mumps, rubella vaccine and hepatitis A and B vaccine and experienced very strong reactions including a golf-ball sized ball in her arm on the 3rd hepatitis A and hepatitis B dose that required steroids to bring it down. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the arm left on 10Mar2021 at 07:15 for COVID-19 immunisation. After the first dose of the vaccination, on 10Mar2021, after three hours, at 10:15, the patient experienced chills and on the next day, 11Mar2021, the patient experienced a hangover-type headache. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to the vaccination the patient had not been diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. For the second dose, the hangover-type headache started on the same day as the shot, 31Mar2021 and experienced sporadic chills on day 2. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatments for the event. The clinical outcome of the events chills and headache were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Fatigue, Myalgia, Nausea
Clinical narrative: Tiredness; Poor sleep; Arm Pain; Swelling; Sore throat; Dizziness; Chills; Muscle aches/pains; Nausea; Night sweats; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6208) via an unspecified route of administration in the right arm on 29Mar2021 at 14:00 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Prior to the vaccination, the patient was not tested positive for COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had not received any other vaccines within 4 weeks prior to COVID vaccine. Concomitant medications included vitamin c (NATURES BOUNTY) and HUM pre and probiotics (MANUFACTURER UNKOWN) started on an unknown date for unspecified indication.  On 29Mar2021 at 16:00, the patient experienced tiredness, poor sleep, arm pain, swelling, sore throat, dizziness, chills, muscle aches or pains, nausea and night sweats but no fever. The patient did not receive any treatment for the adverse events. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the events tiredness, poor sleep, arm pain, swelling, sore throat, dizziness, chills, muscle aches or pains, nausea and night sweats was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Night sweats, Oropharyngeal pain, Pain in extremity, Poor quality sleep, Swelling
Clinical narrative: Tiredness; Poor sleep; Arm Pain; Swelling; Sore throat; Dizziness; Chills; Muscle aches/pains; Nausea; Night sweats; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6208) via an unspecified route of administration in the right arm on 29Mar2021 at 14:00 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Prior to the vaccination, the patient was not tested positive for COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had not received any other vaccines within 4 weeks prior to COVID vaccine. Concomitant medications included vitamin c (NATURES BOUNTY) and HUM pre and probiotics (MANUFACTURER UNKOWN) started on an unknown date for unspecified indication.  On 29Mar2021 at 16:00, the patient experienced tiredness, poor sleep, arm pain, swelling, sore throat, dizziness, chills, muscle aches or pains, nausea and night sweats but no fever. The patient did not receive any treatment for the adverse events. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the events tiredness, poor sleep, arm pain, swelling, sore throat, dizziness, chills, muscle aches or pains, nausea and night sweats was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Cough, Nasal congestion, Pain, Pyrexia
Clinical narrative: Fever; Chills; Cough; Lung irritation; Nasal congestion; Aches; This is a spontaneous report from a contactable other health care professional, the patient. A 32-year-old non-pregnant female patient received unspecified dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: Unknown) via unspecified route of administration in the right arm on 30Mar2021, at 13:15 as a single dose for COVID-19 immunisation (at the age of 32-years-old). Medical history included neck injury and allergy to sulfa antibiotics. Concomitant medications included sertraline hydrochloride (ZOLOFT), tramadol (MANUFACTURER UNKNOWN), carisoprodol (SOMA), paracetamol (TYLENOL), ibuprofen (MOTRIN), and magnesium (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was diagnosed with COVID-19 in Dec2020, on unknown date. Since the vaccination, the patient had not been tested for COVID-19. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 31Mar2021, at 16:00 the patient experienced fever, aches, chills, cough, lung irritation, and nasal congestion. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, emergency room/department or urgent care. The patient had not received treatment for events. The clinical outcome of events fever, aches, chills, cough, lung irritation, and nasal congestion was not resolved at the time of this report.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Respiratory tract irritation
Clinical narrative: Fever; Chills; Cough; Lung irritation; Nasal congestion; Aches; This is a spontaneous report from a contactable other health care professional, the patient. A 32-year-old non-pregnant female patient received unspecified dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: Unknown) via unspecified route of administration in the right arm on 30Mar2021, at 13:15 as a single dose for COVID-19 immunisation (at the age of 32-years-old). Medical history included neck injury and allergy to sulfa antibiotics. Concomitant medications included sertraline hydrochloride (ZOLOFT), tramadol (MANUFACTURER UNKNOWN), carisoprodol (SOMA), paracetamol (TYLENOL), ibuprofen (MOTRIN), and magnesium (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was diagnosed with COVID-19 in Dec2020, on unknown date. Since the vaccination, the patient had not been tested for COVID-19. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 31Mar2021, at 16:00 the patient experienced fever, aches, chills, cough, lung irritation, and nasal congestion. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, emergency room/department or urgent care. The patient had not received treatment for events. The clinical outcome of events fever, aches, chills, cough, lung irritation, and nasal congestion was not resolved at the time of this report.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Insomnia
Clinical narrative: Sleeplessness; exhausted; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the arm left on 09Mar2021 at 11:30 (at the age of 54-year-old) as a single dose for COVID-19 immunisation. Medical history included sleep apnea and allergy to walnuts. Concomitant medications included unspecified anaesthetic (MANUFACURER UNKNOWN) started on an unknown date for root canal procedure at dentist and ibuprofen (IBUPROFEN) started on an unknown date for an unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Mar2021 at 04:00, the patient experienced sleeplessness. The patient had been unable to sleep for more than a few hours at a time. At first, the patient thought it was psychological (excitement/ anxiety) but this had persisted for weeks and it was unprecedented since the first shot. The patient also reported that he was usually exhausted by mid afternoon or early evening and often took a nap.  The patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the right arm on 30Mar2021 at 09:45 (at the age of 54-year-old), as a single dose for COVID-19 immunisation. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events sleeplessness and exhausted was not resolved at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Pain in extremity, Vaccination site pain
Clinical narrative: Injection site soreness; arm soreness; tiredness; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8733), via an unspecified route of administration in the left arm on 30Mar2021 at 15:30 (at the age of 51-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Patient had no known allergies to medications, food, or other products. Concomitant medications included calcium carbonate, magnesium carbonate, magnesium trisilicate (TUMS) for an unknown indication from an unknown date. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 30Mar2021 at 16:00, the patient experienced injection site soreness, arm soreness and tiredness. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of injection site soreness, arm soreness and tiredness were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Vertigo, Vomiting
Clinical narrative: Vertigo; Vomiting; This is a spontaneous report from a contactable consumer, the patient. A 43-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA Vaccine; Lot number: UNKNOWN), via an unspecified route of administration in the right arm on 23Mar2021 at 13:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation Medical history included possible Grave's Disease, untreated. Concomitant medications included amoxicillin and clavulanic acid (AUGMENTIN); levocabastine hydrochloride (ZYRTEC); MEGARED and Hibiscus Flower (MANUFACTURER UNKNOWN) taken for an unknown indication from an unknown start date and unknown if ongoing. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 23Mar2021 at 13:45, 30 minutes after vaccination, the patient experienced vertigo and vomiting. No therapeutic measures were taken for the adverse events. The clinical outcome of the events vertigo and vomiting was recovered on an unknown date at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Headache, Malaise
Clinical narrative: still feel a bit weak; had a pretty strong response to it, was completely out yesterday,; headaches; This is a spontaneous report from a contactable consumer. An adult female patient of unknown age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 31Mar2021 as a single dose for COVID-19 immunisation. Medical history and concomitant medications were unknown. It was unknown if the patient had any allergies to food, medications, or other products. It was unknown if the patient was pregnant at the time of vaccination. It was unknown if the patient was diagnosed with COVID-19 prior to the vaccination. It was unknown if the patient had been tested for COVID-19 since the vaccination. It was unknown if the patient received any other vaccines within four weeks prior to the vaccination. On 31Mar2021, the patient got the second vaccine and had a pretty strong response to it and was completely out. The patient still felt a bit weak, but the headaches were gone. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. It was unknown if the patient received any treatment for the events had a pretty strong response to it, was completely out yesterday, felt a bit weak and headaches. The clinical outcome of the event headaches was resolved on an unknown date in 2021 while that of had a pretty strong response to it, was completely out yesterday and felt a bit weak was unknown at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Headache, Pain in extremity
Clinical narrative: feeling weak; headache; Arm pain; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3248) via an unspecified route of administration in the arm left on 30Mar2021 at 13:45 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included single functional kidney. The patient had known allergies to epinephrine and lobster. The patient did not receive any other medications within two weeks of the COVD-19 vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the arm left on 09Mar2021 at 13:45 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient had not been diagnosed with COVID-19. Since the vaccination the patient had not been tested for COVID-19. On 30Mar2021, Tuesday, at 22:00, the patient experienced pain in his arm. On 31Mar2021, Wednesday ,the patient experienced feeling weak, which got worse as the day progressed. The patient developed headache. The patient felt weak and had headache all day, and started feeling better at night. The patient felt a bit weak the next day but everything else seemed to be fine. Therapeutic measures for headache included treatment with Tylenol which was ineffective. The clinical outcome of the events pain in arm, feeling weak and headache was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: unusual headache; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the left arm on 28Feb2021 at 13:15 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history included papillary thyroid cancer. Concomitant medications included levothyroxine sodium (SYNTHROID) for unknown indication from an unknown date received within 2 weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medication, food, or other products. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to COVID vaccination. On 28Feb2021 at 18:30, the patient experienced unusual headache started about 5-6 hours post injection and low-grade ache that came from the middle of the head and made her to reach in and rub it. Headache was not there for about 24 hours on 6Mar2021. No therapeutic measures were taken as a result of the event. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the event headache was recovered on 10Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 82.0
Sex: F
Vaccine: COVID19
Symptoms: Breast swelling, Erythema, Lymphadenopathy
Clinical narrative: Swollen lymph nodes under left arm; swollen left breast; redness on breast; This is a spontaneous report from a contactable consumer, the patient. An 82-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6201) via an unspecified route of administration in the left arm on 15Feb2021 (at the age of 82-years-old), as a single dose for COVID-19 immunisation. Medical history included allergic to wasp bites. Concomitant medications received within two weeks of vaccination included statin (MANUFACTURER UNKNOWN), for unknown indication from an unknown date. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL8982) via an unspecified route of administration in the left arm on 25Jan2021 at 00:00 (at the age of 82-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 19Feb2021, the patient experienced swollen lymph nodes under left arm, swollen left breast and also redness on breast. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events swollen lymph nodes under left arm, swollen left breast and redness on breast was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Alopecia, SARS-CoV-2 test
Clinical narrative: balding; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 03Mar2021 at 19:00 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the arm left on 27Mar2021 at 15:00 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. The patient had medical history that was unspecified and has known allergies. The patient received other medications within 2 weeks of vaccination that were unspecified. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Since the vaccination the patient had been tested for COVID-19. The patient had undergone COVID-19 test on 08Mar2021, and was tested negative. On 17Mar2021, may be 2 weeks after the first COVID-19 vaccine, the patient noticed when combing her hair, that she started to see a comb full of hair instead of few strands, and hair in the top was gone as patient was balding. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. The clinical outcome of the event balding was not recovered at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Tachycardia
Clinical narrative: Tachycardia heartbeat; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 28Mar2021 at 11:15 (at the age of 48-year-old), as a single dose for COVID-19 immunisation. Medical history included epilepsy, blood pressure high and fruit allergy (avocados). Concomitant medications included benazepril (MANUFACTURER UNKNOWN), hydrochlorothiazide (MANUFACTURER UNKNOWN), valproate semi sodium (DEPAKOTE) and carbamazepine (CARBAMA), all taken for an unknown indication, since unspecified dates. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 31Mar2021 at 16:00, the patient experienced tachycardia heartbeat. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the tachycardia heartbeat. The clinical outcome of the event tachycardia was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Nausea, Urticaria
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613), via an unspecified route of administration in the right arm on 27Mar2021 at 11:30 (at the age of 57-years-old), as a single dose for COVID-19 immunisation. Medical history included thyroid disorder. The patient had no known allergies. Concomitant medications included penicillin (MANUFACTURER UNKNOWN), levothyroxine (MANUFACTURER UNKNOWN) and estradiol (MANUFACTURER UNKNOWN); all for unknown indications from an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 28Mar2021 at 09:00, the patient experienced severe headaches and nausea. On 01Apr2021, 5 days after the vaccination, the patient experienced hives on left lower leg. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the severe headaches, nausea and hives were not recovered at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 20.0
Sex: F
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Headache; This is a spontaneous report from a contactable consumer, the parent. A 20-year-old non-pregnant female patient received unspecified dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) via an unspecified route of administration in the arm left on 31Mar2021(at the age of 20-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history reported. The patient received concomitant medication included unspecified birth control within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021, the patient experienced headache. The events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event headache was recovered on 01Apr2021 at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: Joint swelling
Clinical narrative: Swelling in right knee; This is a spontaneous report from a non-contactable consumer, the patient. A 43-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the right arm on 25Mar2021 at 11:30 as a single dose (at the age of 43-years-old) for COVID-19 immunisation. The medical history of the patient was reported as none. The patient had no known allergies to medications, food, or other products. The patient did not receive any other medications within 2 weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 26Mar2021 at 10:00, the patient experienced swelling in right knee. The patient did not receive any treatment for the reported event. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event swelling in right knee was recovering at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Axillary pain, Body temperature, Dysgeusia, Pain
Clinical narrative: Ran a 102-4 degree fever for approximately 36 hours, followed by a 101 degree fever currently.; I have large painful lumps in both armpits (golf ball size).; I have large painful lumps in both armpits (golf ball size).; I have had full bodyaches,; joint pain; chills during fevers, especially at night.; I have a very prominent metallic taste in my mouth.; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 30Mar2021 at 10:00 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma, hypothyroidism and depression. Concomitant medications included bupropion hydrochloride 160 (WELLBUTRIN), levothyroxine .50 (MANUFACTURER UNKNOWN)) and fluticasone propionate; salmeterol xinafoate 250 (ADVAIR); all taken from an unspecified date for an unknown indication. The patient was allergic to latex, kiwi, avocado, banana, pineapple and mango. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 09Mar2021 at 12:00 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 30Mar2021 at 20:00, the patient experienced 102 - 4 degree fever for approximately 36 hours, followed by a 101 degree fever currently. The patient had large painful lumps in both armpits (golf ball size); also had full body aches, joint pain, and chills during fevers, especially at night. The patient had very prominent metallic taste in my mouth. The event did not result in doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events fever, swelling, armpit pain, general body pain, joint pain, fever chills and taste metallic were not resolving at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Swelling
Clinical narrative: Ran a 102-4 degree fever for approximately 36 hours, followed by a 101 degree fever currently.; I have large painful lumps in both armpits (golf ball size).; I have large painful lumps in both armpits (golf ball size).; I have had full bodyaches,; joint pain; chills during fevers, especially at night.; I have a very prominent metallic taste in my mouth.; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 30Mar2021 at 10:00 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma, hypothyroidism and depression. Concomitant medications included bupropion hydrochloride 160 (WELLBUTRIN), levothyroxine .50 (MANUFACTURER UNKNOWN)) and fluticasone propionate; salmeterol xinafoate 250 (ADVAIR); all taken from an unspecified date for an unknown indication. The patient was allergic to latex, kiwi, avocado, banana, pineapple and mango. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 09Mar2021 at 12:00 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 30Mar2021 at 20:00, the patient experienced 102 - 4 degree fever for approximately 36 hours, followed by a 101 degree fever currently. The patient had large painful lumps in both armpits (golf ball size); also had full body aches, joint pain, and chills during fevers, especially at night. The patient had very prominent metallic taste in my mouth. The event did not result in doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events fever, swelling, armpit pain, general body pain, joint pain, fever chills and taste metallic were not resolving at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Fatigue, SARS-CoV-2 test
Clinical narrative: Fatigue,; very bad chills after 24 hours after first dose; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: er8764) via an unspecified route of administration on 31Mar2021 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Concomitant medications were not reported. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 01Apr2021 (reported as 31Mar2021) (after 24 hours of first dose), the patient experienced fatigue and very bad chills. It was unknown if the patient received any treatment for the reported event. On 08Oct2020, the patient had nasal swab for COVID-19 test and resulted positive. On an unknown date, the patient had nasal swab and resulted negative (reported as thrice). The clinical outcome of events fatigue and very bad chills were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Night sweats, Pyrexia
Clinical narrative: Night/sleep sweats; Fever; headache; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm (also reported as left shoulder) on 28Mar2021 at 15:30 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient did not have any allergies to food, medications, or other products. The patient did not receive any concomitant medications. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021 at 09:00, within 48 hours of the vaccine, the patient experienced fever that went away on 31Mar2021 (reported as next day). The patient also experienced night/sleep sweats and headache within the 48 hours which were still present. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events fever, night/sleep sweats and headache. The clinical outcome of the event fever was resolved on 31Mar2021 while that of night/sleep sweats and headache was not resolved at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Fungal infection, Tongue blistering
Clinical narrative: Blisters on tongue; Yeast infection symptoms; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA Vaccine; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 31Mar2021 at 13:00 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history included diabetes. The patient had allergy to sartans. Concomitant medication included insulin aspart (NOVOLOG) since an unknown date for unknown indication. The patient previously took rabies vaccine inact (chick embryo) (MANUFACTURER UNKNOWN) on an unknown date for unknown indication and experienced allergy to vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 31Mar2021 at 21:00, the patient experienced blisters on tongue. About 8 to 9 hours after vaccination, the patient got yeast infection symptoms. The patient did not receive any treatment for the events. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events blisters on tongue and yeast infection symptoms were unknown at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema
Clinical narrative: rash at injection site (raised, circular red rash); This is a spontaneous report from a contactable consumer, the patient. A 30-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP-6955), via an unspecified route of administration in the left arm on 26Mar2021 at 12:00, (at the age of 30-years-old), as a single dose for COVID-19 immunisation. Medical history included anxiety, treenuts allergy, shellfish allergy and melons allergy. Concomitant medications included sertraline (MANUFACTURER UNKNOWN) and ethinylestradiol, norethisterone (ALYACEN); both for unspecified indication from unknown dates. The patient previously took amoxicillin (MANUFACTURER UNKNOWN) and CECLOR; both for unspecified indication and experienced drug allergy.  The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL-3247), via an unspecified route of administration in the left arm on an unspecified date in Mar2021 at 12:00 (at the age of 30-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 31Mar2021 at 22:00, the patient experienced rash at injection site (raised, circular red rash). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event vaccination site erythema was not recovered at the time of reporting.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Body mass index, Diarrhoea, Fatigue, Heart rate, Heart rate increased
Clinical narrative: Severe diarrhea for three days; Nausea; Fatigue; Heart was slightly elevated; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the arm left on 27Mar2021 at 13:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included gallbladder removal and obesity (BMI 49). The patient had no allergies to medications, food, or other products. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27Mar2021, at 14:30, the patient experienced severe diarrhea, nausea, fatigue and heart was slightly elevated. The patient reported that she had severe diarrhea for three days following vaccination date along with other side effects like nausea, fatigue and her heart was slightly elevated than normal rates. She stated that, she was reporting this in hope of bringing awareness for others without gall bladders and high BMI. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events severe diarrhea, nausea, fatigue and heart was slightly elevated was recovered/resolved with sequelae on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea
Clinical narrative: Severe diarrhea for three days; Nausea; Fatigue; Heart was slightly elevated; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the arm left on 27Mar2021 at 13:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included gallbladder removal and obesity (BMI 49). The patient had no allergies to medications, food, or other products. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27Mar2021, at 14:30, the patient experienced severe diarrhea, nausea, fatigue and heart was slightly elevated. The patient reported that she had severe diarrhea for three days following vaccination date along with other side effects like nausea, fatigue and her heart was slightly elevated than normal rates. She stated that, she was reporting this in hope of bringing awareness for others without gall bladders and high BMI. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events severe diarrhea, nausea, fatigue and heart was slightly elevated was recovered/resolved with sequelae on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Malaise, Pain in extremity
Clinical narrative: fatigue; extreme pain in lower extremities; headache; general feeling of being unwell; This is a spontaneous report from a contactable pharmacist. A 65-year-old male patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 30Mar2021(at the age of 65-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history and concomitant medications. The patient did not had allergy to any medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 31Mar2021, at 23:00 the patient began to experience fatigue, extreme pain in lower extremities, headache, and general feeling of being unwell. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the events fatigue, extreme pain in lower extremities, headache, and general feeling of being unwell were recovered on an unknown date.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia
Clinical narrative: Metallic taste in my mouth; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on 11Mar2021 at 10:30 am (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism (Just Thyroid (Hypo) - had been taking medication close to 20 years). The patient did not have allergies to medications, food, or other products. Concomitant medications included levothyroxine sodium (SYNTHROID) of 0.025 mg daily and omeprazole (MANUFACTURER UNKNOWN) 20 - daily OTC on an unknown date for unspecified indication. The patient also previously received the first dose of BNT162B2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: EM9810) via an unspecified route of administration in the left arm on 11Feb2021 at 10:30 am (at the age of 51-years-old) as a single dose for Covid-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Post vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Mar2021, the patient experienced metallic taste. The patient reported that she woke up with metallic taste in her mouth that did not go away. She did not have infection in her mouth, and it also could be from sinus drainage, but she never had this type of taste in her mouth. The patient did not receive any treatment for the reported adverse event. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event metallic taste was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.